Get the Stockscreener App
84.59
1.17%
-1.00
After Hours:
84.59
Biomarin Pharmaceutical Inc stock is traded at $84.59, with a volume of 1.02M.
It is down -1.17% in the last 24 hours and down -0.77% over the past month.
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
See More
Previous Close:
$85.59
Open:
$85.66
24h Volume:
1.02M
Market Cap:
$16.06B
Revenue:
$2.47B
Net Income/Loss:
$205.46M
P/E Ratio:
110.04
EPS:
0.7687
Net Cash Flow:
$163.21M
1W Performance:
+0.59%
1M Performance:
-0.77%
6M Performance:
-6.91%
1Y Performance:
-3.07%
1D Range:
$84.07
$86.45
52W Range:
$73.67
$99.56
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Natixis Trims Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
MarketBeat
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical - Yahoo Finance
Yahoo Finance
BioMarin Pharmaceutical (NASDAQ:BMRN) Receives Hold Rating from Canaccord Genuity Group - Defense World
Defense World
BioMarin Pharmaceutical's (BMRN) "Hold" Rating Reiterated at Canaccord Genuity Group - MarketBeat
MarketBeat
Pharma Pulse 7/25/24: Driving CAR-Ts for Treatment in Cancer and Immunology, CrowdStrike Explains What Went Wrong in Global Outage & more - Pharmaceutical Executive
Pharmaceutical Executive
FDA approves BioMarin’s BRINEURA for children under 3 years with CLN2 disease - PharmaLive
PharmaLive
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biomarin Pharmaceutical Inc Stock (BMRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MEIER RICHARD A | Director |
Jun 03 '24 |
Option Exercise |
63.10 |
6,600 |
416,460 |
126,227 |
| HERON ELAINE J | Director |
Jun 03 '24 |
Option Exercise |
63.10 |
5,047 |
318,466 |
101,888 |
| Mueller Brian | EVP, Chief Financial Officer |
May 30 '24 |
Option Exercise |
63.10 |
5,000 |
315,500 |
77,159 |
| Mueller Brian | EVP, Chief Financial Officer |
May 30 '24 |
Sale |
75.19 |
5,000 |
375,950 |
72,159 |
| Davis George Eric | EVP, Chief Legal Officer |
May 28 '24 |
Option Exercise |
63.10 |
40,850 |
2,577,635 |
97,007 |
| Davis George Eric | EVP, Chief Legal Officer |
May 28 '24 |
Sale |
74.51 |
40,850 |
3,043,802 |
56,157 |
| BIENAIME JEAN JACQUES | Director |
May 10 '24 |
Option Exercise |
63.10 |
20,000 |
1,262,000 |
494,994 |
| BIENAIME JEAN JACQUES | Director |
May 10 '24 |
Sale |
81.14 |
20,000 |
1,622,800 |
474,994 |
| BIENAIME JEAN JACQUES | Director |
May 09 '24 |
Option Exercise |
63.10 |
20,000 |
1,262,000 |
494,994 |
| BIENAIME JEAN JACQUES | Director |
May 09 '24 |
Sale |
81.62 |
20,000 |
1,632,400 |
474,994 |
0.45%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):